Six weeks of daily rifapentine vs. a comparator arm of 12-16 week rifamycin-based treatment of latent M. tuberculosis infection: assessment of safety, tolerability and effectiveness - ASTERoiD
Lay Description
Category
- Immune System
- Infections / Infectious Diseases
- IRB Number
- 20180194HU
- NCT Number
- NCT # not yet entered
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Sanjuanita Medina
medinas5@uthscsa.edu
Irma Scholler
210-450-3150
scholler@uthscsa.edu
Principal Investigator
Jose Cadena Zuluaga